Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids.

ABSTRACT:

Objective

This study evaluated the effect of the systemic immune-inflammation index/albumin ratio (SII/ALB) on the prognosis of immunotherapy-treated patients receiving opioids.

Methods

A retrospective analysis was conducted of 185 immunotherapy-treated patients who received opioids at Xuzhou Central Hospital from 01/09/2021 to 01/09/2023. The results of related clinical data were collected during the week before the cancer patients received immunotherapy. The SII/ALB cut-off value was determined, and the relationship between the SII/ALB and clinical pathological parameters was analyzed using the chi-square test. The effect of the SII/ALB on progression-free survival (PFS) was examined using Kaplan-Meier curves and the Cox proportional hazard model.

Result

The SII/ALB

SUBMITTER: Yan L 

PROVIDER: S-EPMC11210763 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature